ADARx Pharmaceuticals (ADRX)
ADARx Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, large holders and insider trades. Listed on Nasdaq.
1.2M
Short interest
settlement 2026-09-30
1.7
Days to cover
74.5%
Short share of volume
2026-10-23
142,681
Fails to deliver
settlement 2026-09-30
$87.7M
Insider flow, 90 days
13 buys, 0 sells
As of 2026-10-23.
Short interest
FINRA, twice a month. The newest 1 settlements in the table. JSON| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 1,163,375 | +100.0% | 669,771 | 1.74 |
Daily short volume
FINRA Reg SHO, the last 21 sessions. JSONAs of 23 October 2026, the short share of ADRX volume is 74.5%, up 9.7 points over the last five sessions. Over the last 21 readings it ranged from 27.6% (20 October 2026) to 90.8% (9 October 2026). The latest reading is 12.5 points above the 21-session average of 62.0%, on 80K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-23 | 59K | 80K | 74.5% | 0 |
| 2026-10-22 | 40K | 66K | 60.4% | 0 |
| 2026-10-21 | 109K | 204K | 53.4% | 0 |
| 2026-10-20 | 181K | 658K | 27.6% | 0 |
| 2026-10-19 | 114K | 144K | 79.3% | 0 |
| 2026-10-16 | 89K | 137K | 64.8% | 111 |
| 2026-10-15 | 96K | 159K | 60.5% | 0 |
| 2026-10-14 | 125K | 169K | 73.9% | 0 |
| 2026-10-13 | 63K | 92K | 68.4% | 0 |
| 2026-10-12 | 93K | 115K | 80.8% | 0 |
| 2026-10-09 | 370K | 407K | 90.8% | 0 |
| 2026-10-08 | 180K | 211K | 85.2% | 0 |
| 2026-10-07 | 318K | 373K | 85.2% | 0 |
| 2026-10-06 | 385K | 584K | 65.9% | 46,241 |
| 2026-10-05 | 231K | 519K | 44.5% | 0 |
| 2026-10-02 | 199K | 324K | 61.4% | 0 |
| 2026-10-01 | 299K | 429K | 69.8% | 0 |
| 2026-09-30 | 170K | 313K | 54.4% | 0 |
| 2026-09-29 | 121K | 270K | 44.8% | 0 |
| 2026-09-28 | 169K | 602K | 28.1% | 0 |
| 2026-09-25 | 428K | 1.5M | 28.0% | 175 |
Fails to deliver
SEC, the last 2 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in ADRX is 142,681 shares, up 110,974 shares over the last settlement date.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 142,681 | $20.64 | $2.9M |
| 2026-09-28 | 31,707 | $19.35 | $614K |
Insider trades
SEC Form 4, newest first. JSONInsiders at ADRX reported 13 open-market buys worth $87.7M in the last 90 days and no open-market sells. Latest filing: LAV Biosciences Fund V, L.P. (10% owner) on 2026-09-28.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-28 | LAV Biosciences Fund V, L.P. | 10% owner | Conversion | 308K | price not stated in the filing | not stated | 308K |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | 10% owner | Buy | 593K | $17.00 | $10.1M | 593K |
| 2026-09-28 | George Simeon | Director, 10% owner | Buy | 593K | $17.00 | $10.1M | 593K |
| 2026-09-28 | ORBIMED ADVISORS LLC | Director, 10% owner | Buy | 588K | $17.00 | $10.0M | 588K |
| 2026-09-28 | ORBIMED ADVISORS LLC | Director, 10% owner | Buy | 62K | $17.00 | $1.0M | 9.3M |
| 2026-09-28 | ORBIMED ADVISORS LLC | Director, 10% owner | Conversion | 256K | price not stated in the filing | not stated | 9.2M |
| 2026-09-28 | ORBIMED ADVISORS LLC | Director, 10% owner | Conversion | 513K | price not stated in the filing | not stated | 9.0M |
| 2026-09-28 | ORBIMED ADVISORS LLC | Director, 10% owner | Conversion | 1.3M | price not stated in the filing | not stated | 8.5M |
| 2026-09-28 | ORBIMED ADVISORS LLC | Director, 10% owner | Conversion | 7.1M | price not stated in the filing | not stated | 7.1M |
| 2026-09-28 | ORBIMED ADVISORS LLC | Director, 10% owner | Buy | 300K | $17.00 | $5.1M | 14.3M |
| 2026-09-28 | ORBIMED ADVISORS LLC | Director, 10% owner | Conversion | 564K | price not stated in the filing | not stated | 14.0M |
| 2026-09-28 | ORBIMED ADVISORS LLC | Director, 10% owner | Conversion | 770K | price not stated in the filing | not stated | 13.5M |
| 2026-09-28 | ORBIMED ADVISORS LLC | Director, 10% owner | Conversion | 2.0M | price not stated in the filing | not stated | 12.7M |
| 2026-09-28 | ORBIMED ADVISORS LLC | Director, 10% owner | Conversion | 10.7M | price not stated in the filing | not stated | 10.7M |
| 2026-09-28 | GORDON CARL L | Director, 10% owner | Buy | 588K | $17.00 | $10.0M | 588K |
| 2026-09-28 | GORDON CARL L | Director, 10% owner | Buy | 62K | $17.00 | $1.0M | 9.3M |
| 2026-09-28 | GORDON CARL L | Director, 10% owner | Conversion | 256K | price not stated in the filing | not stated | 9.2M |
| 2026-09-28 | GORDON CARL L | Director, 10% owner | Conversion | 513K | price not stated in the filing | not stated | 9.0M |
| 2026-09-28 | GORDON CARL L | Director, 10% owner | Conversion | 1.3M | price not stated in the filing | not stated | 8.5M |
| 2026-09-28 | GORDON CARL L | Director, 10% owner | Conversion | 7.1M | price not stated in the filing | not stated | 7.1M |
| 2026-09-28 | GORDON CARL L | Director, 10% owner | Buy | 300K | $17.00 | $5.1M | 14.3M |
| 2026-09-28 | GORDON CARL L | Director, 10% owner | Conversion | 564K | price not stated in the filing | not stated | 14.0M |
| 2026-09-28 | GORDON CARL L | Director, 10% owner | Conversion | 770K | price not stated in the filing | not stated | 13.5M |
| 2026-09-28 | GORDON CARL L | Director, 10% owner | Conversion | 2.0M | price not stated in the filing | not stated | 12.7M |
| 2026-09-28 | GORDON CARL L | Director, 10% owner | Conversion | 10.7M | price not stated in the filing | not stated | 10.7M |
| 2026-09-28 | Chimovits Erez | Director | Buy | 62K | $17.00 | $1.0M | 9.3M |
| 2026-09-28 | Chimovits Erez | Director | Conversion | 256K | price not stated in the filing | not stated | 9.2M |
| 2026-09-28 | Chimovits Erez | Director | Conversion | 513K | price not stated in the filing | not stated | 9.0M |
| 2026-09-28 | Chimovits Erez | Director | Conversion | 1.3M | price not stated in the filing | not stated | 8.5M |
| 2026-09-28 | Chimovits Erez | Director | Conversion | 7.1M | price not stated in the filing | not stated | 7.1M |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | 10% owner | Conversion | 308K | price not stated in the filing | not stated | 308K |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | 10% owner | Conversion | 154K | price not stated in the filing | not stated | 11.2M |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | 10% owner | Conversion | 513K | price not stated in the filing | not stated | 11.1M |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | 10% owner | Conversion | 1.7M | price not stated in the filing | not stated | 10.6M |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | 10% owner | Conversion | 8.9M | price not stated in the filing | not stated | 8.9M |
| 2026-09-28 | George Simeon | Director, 10% owner | Conversion | 169K | price not stated in the filing | not stated | 1.8M |
| 2026-09-28 | George Simeon | Director, 10% owner | Conversion | 1.7M | price not stated in the filing | not stated | 1.7M |
| 2026-09-28 | George Simeon | Director, 10% owner | Buy | 415K | $17.00 | $7.1M | 2.0M |
| 2026-09-28 | George Simeon | Director, 10% owner | Conversion | 1.5M | price not stated in the filing | not stated | 1.5M |
| 2026-09-28 | George Simeon | Director, 10% owner | Buy | 593K | $17.00 | $10.1M | 5.6M |
| 2026-09-28 | George Simeon | Director, 10% owner | Conversion | 513K | price not stated in the filing | not stated | 5.0M |
| 2026-09-28 | George Simeon | Director, 10% owner | Conversion | 1.1M | price not stated in the filing | not stated | 4.4M |
| 2026-09-28 | George Simeon | Director, 10% owner | Conversion | 3.3M | price not stated in the filing | not stated | 3.3M |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | 10% owner | Conversion | 169K | price not stated in the filing | not stated | 1.8M |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | 10% owner | Conversion | 1.7M | price not stated in the filing | not stated | 1.7M |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | 10% owner | Buy | 415K | $17.00 | $7.1M | 2.0M |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | 10% owner | Conversion | 1.5M | price not stated in the filing | not stated | 1.5M |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | 10% owner | Buy | 593K | $17.00 | $10.1M | 5.6M |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | 10% owner | Conversion | 513K | price not stated in the filing | not stated | 5.0M |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | 10% owner | Conversion | 1.1M | price not stated in the filing | not stated | 4.4M |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | 10% owner | Conversion | 3.3M | price not stated in the filing | not stated | 3.3M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON11 holders report 5% or more of ADRX in their latest filing, 8 on Schedule 13D (active intent). The largest reported stake is ORBIMED ADVISORS LLC at 14.0% of the class (14,913,764 shares), filed 2026-10-02 for an event on 2026-09-28.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-16 | 13G | Yi Shiindividual | 11.9M | 11.1% | 2026-09-30 |
| 2026-10-16 | 13G | LAV Biosciences Fund V, L.P.partnership | 11.2M | 10.5% | 2026-09-30 |
| 2026-10-16 | 13G | LAV Fund VI Opportunities, L.P.partnership | 308K | 0.3% | 2026-09-30 |
| 2026-10-16 | 13G | LAV Fund VI, L.P.partnership | 308K | 0.3% | 2026-09-30 |
| 2026-10-05 | 13D | SR One Capital Management, LLCother entity | 9.9M | 9.3% | 2026-09-28 |
| 2026-10-05 | 13D | Simeon Georgeindividual | 9.9M | 9.3% | 2026-09-28 |
| 2026-10-05 | 13D | SR One Capital Fund I Aggregator, LPpartnership | 5.6M | 5.2% | 2026-09-28 |
| 2026-10-05 | 13D | SR One Capital Partners I, LPpartnership | 5.6M | 5.2% | 2026-09-28 |
| 2026-10-05 | 13D | SR One Capital Opportunities Fund I, LPpartnership | 2.0M | 1.8% | 2026-09-28 |
| 2026-10-05 | 13D | SR One Capital Opportunities Partners I, LPpartnership | 2.0M | 1.8% | 2026-09-28 |
| 2026-10-05 | 13D | SR One Co-Invest III Manager, LLCother entity | 1.8M | 1.7% | 2026-09-28 |
| 2026-10-05 | 13D | SR One Co-Invest III, LLCother entity | 1.8M | 1.7% | 2026-09-28 |
| 2026-10-05 | 13D | SR One Capital SMA Partners, LPpartnership | 593K | 0.6% | 2026-09-28 |
| 2026-10-05 | 13D | AMZL, LPpartnership | 593K | 0.6% | 2026-09-28 |
| 2026-10-02 | 13D | ORBIMED ADVISORS LLCinvestment adviser | 14.9M | 14.0% | 2026-09-28 |
| 2026-10-02 | 13D | ORBIMED CAPITAL GP VII LLCother entity | 14.3M | 13.4% | 2026-09-28 |
| 2026-10-02 | 13D | ORBIMED ADVISORS ISRAEL II LTDcorporation | 9.3M | 8.7% | 2026-09-28 |
| 2026-10-02 | 13D | ORBIMED ISRAEL GP II, L.P.partnership | 9.3M | 8.7% | 2026-09-28 |
| 2026-10-02 | 13D | OrbiMed Genesis GP LLCother entity | 588K | 0.6% | 2026-09-28 |
| 2026-10-01 | 13G | BCLS Fund III Investments, LPpartnership | 6.7M | 6.3% | 2026-09-24 |
What this page is
ADARx Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows ADARx Pharmaceuticals (ADRX), SEC CIK 1802369, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-23.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-16.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-28.JSON and CSV
- Company record
- EDGAR filing index for CIK 1802369Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other company pages
- MLMMartin Marietta Materials
- MMM3M
- MNSTMonster Beverage
- MOAltria Group
- MODModine Manufacturing
- MOSMosaic
- MPMP Materials
- MPCMarathon Petroleum
- MPWRMonolithic Power Systems
- MRKMerck
- MRNAModerna
- MRSHMarsh & McLennan Companies
- MRVLMarvell Technology
- MSMorgan Stanley
- MSCIMSCI
- MSFTMicrosoft
- MSIMotorola Solutions
- MSTRStrategy
- MTBM&T Bank
- MTCHMatch Group
- MTDMettler-Toledo International
- MTNVail Resorts
- MTSIMACOM Technology Solutions Holdings
- MTZMasTec
Datasets
Frequently Asked Questions
How much of ADRX is sold short?
1,163,375 shares were held short at the 2026-09-30 settlement, 1.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ADRX's daily short volume?
On 2026-10-23, 59,348 of the 79,717 ADRX shares reported to FINRA were sold short, 74.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ADRX have fails to deliver?
The SEC's latest file shows 142,681 ADRX shares failed to deliver at settlement 2026-09-30. Fails are reported per settlement date and published twice a month with a lag.
Are ADRX insiders buying or selling?
Insiders at ADRX reported 13 open-market buys worth $87.7M in the last 90 days and no open-market sells. Latest filing: LAV Biosciences Fund V, L.P. (10% owner) on 2026-09-28.
Who owns 5% or more of ADRX?
11 holders report 5% or more of ADRX in their latest filing, 8 on Schedule 13D (active intent). The largest reported stake is ORBIMED ADVISORS LLC at 14.0% of the class (14,913,764 shares), filed 2026-10-02 for an event on 2026-09-28.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.